| INTRODUCTION
The increasing incidence of type 1 diabetes (T1D) in children can be attributed to the action of environmental factors in a context of genetic predisposition. Current screening strategies for at-risk individuals are limited by the low specificity of genetic screening in the general population (GP), who make up about 85% of those who develop T1D, 1 and low sensitivity in those with a family history of T1D. More precise identification of children at high risk of developing T1D is important for recruitment into natural history studies to better understand the etiologic factors contributing to islet autoimmunity (IA) and T1D. Moving forward, these strategies will also allow for better identification of individuals who could benefit from both primary and secondary prevention trials. Further, as population screening for † These authors contributed equally to this work.
IA is being explored, 2 better definition of genetic risk could serve as a second line of screening.
The human leukocyte antigen (HLA) region of chromosome 6p21 plays a significant role, conferring up to 50% of the genetic risk for diabetes. 3 In addition, however, more than 50 other genetic susceptibility markers have been associated with development of T1D. 1, [4] [5] [6] [7] [8] [9] While any 1 non-HLA gene may not confer significant risk increase alone, an improvement in prediction strategy can be achieved by giving weight to varying gene contributions. 10 We have previously used multivariable logistic regression and Bayesian feature selection to generate a weighted risk model with single nucleotide polymorphisms (SNPs) selected from 41 genetic susceptibility markers included in data from the Type 1 Diabetes Genetics Consortium (T1DGC) dataset. 10 This 10-factor model included HLA genotype plus 9 SNPs from the PTPN22, INS, IL2RA, ERBB3, ORMDL3, BACH2, IL27, GLIS3, and RNLS genes and was used to predict progression to T1D or multiple islet autoantibody positive status. 10 The model was validated in a group of children and young adults less than 20 years of age with new onset diabetes, 11 and in a group of T1D parents of children with T1D from the German BABYDIAB study, with the non-T1D parents as the control group. 12 In this previous analysis, the 10-factor model showed improved discrimination of those at risk for the development of T1D when compared with HLA genotype alone.
Further, the risk of development of T1D or multiple IA status was significantly higher in the portion of the prospectively followed BABYDIAB cohort with risk scores in the upper quintile when compared to the lower quintile, using Kaplan-Meier analysis. 10 The Diabetes Autoimmunity Study in the Young (DAISY) is a cohort consisting of first-degree relatives (FDR) of T1D patients, similar to the BABYDIAB study. However, unlike BABYDIAB, the DAISY cohort also includes individuals recruited from the GP based on highrisk HLA status. The purpose of the current study was to validate the weighted 10-factor model of HLA plus 9 other SNPs for prediction of development of T1D in participants of the DAISY cohort. Validation in this novel cohort allows examination of the performance of a model developed from a T1D FDR cohort in a group of GP individuals. Further, the performance of this 10-factor model was compared with a more parsimonious 3-factor model or HLA alone.
| METHODS

| Study participants
DAISY is a prospective cohort study that has followed 2547 children at increased risk of T1D for a median of 9 years. The details of screening and follow-up have been previously published. 13 were invited to participate in DAISY. Distribution of HLA types for the GP and FDR subjects is shown in Figure S1 , Supporting Information. Characteristics of FDR and GP participants are shown in 
| Genotyping
Typing for HLA class II alleles at HLA-DRB1, HLA-DQA1, and HLA-DQB1 was previously described. 19, 20 In the DAISY study, genotyping of 9 non-HLA SNPs was as follows:
R620W (rs2476601) polymorphisms were genotyped using a linear array (immobilized probe) method essentially as described in Mirel et al. The following SNPs were genotyped in the laboratory of Dr. Cisca Wijmenga using Illumina GoldenGate Beadexpress assays (veracode 48-plex): IL2RA (rs12251307) and BACH2 (rs11755527).
Taqman SNP genotyping assays (Applied Biosystems, Foster City, California) were utilized to obtain genotype information for GLIS3 (rs7020673), GSDM (rs2290400), ERBB3 (rs2292239), and IL27 (rs4788084) as described previously. 19 All but one of the SNPs used in the Winkler et al risk model 10 were present in the DAISY dataset.
The SNP for IL2RA measured in the DAISY cohort differed from the SNP in the T1DGC study used for development of the Winkler et al 10-factor risk model. 10 The IL2RA SNP from the DAISY dataset (rs12251307) is located in an intergenic region, while the SNP used in the Winkler et al model (rs12722495) 10 is from an intron of IL2RA.
The 2 SNPs were queried for linkage disequilibrium using the Broad Institute SNP Annotation and Proxy Search Pairwise LD tool on the 1000 Genomes Pilot 1 dataset, 21 which resulted in an R 2 of .543 and a D 0 of .843.
HLA risk genotypes were categorized as: 6 = DR3/DR4-DQ8; 5 = DR4-DQ8/DR4-DQ8; 4 = DR3/DR3; 3 = DR4-DQ8/x; 2 = DR3/ DRx; 1 = DRx/DRx (where x represents the non-DR3 and non-DR4-DQ8 alleles). For other SNPs, a score of 2 was given to persons homozygous for the susceptibility allele, 1 when heterozygous, and 0 when homozygous for the non-susceptibility allele.
| Statistical analysis
Demographic characteristics were compared using chi-square analysis for categorical variables and Wilcoxon rank sum tests for continuous variables. Time of follow-up was calculated from birth to age at last visit or diagnosis of T1D. The weights generated by previous analysis 10 were used to calculate risk scores in the DAISY children. Specifically, the risk score per patient i in DAISY was calculated as:
using the weightsβ j and the interceptβ 0 derived in Winkler et al 10 and p is the number of SNPs plus the HLA risk categories. The 9 non-HLA SNPs used in the model were: PTPN22 R620W (rs2476601),
(rs4788084), GLIS3 (rs7020673), and RNLS/C10orf59 (rs10509540) genes. 10 The discriminative power of the model was assessed using receiver operating characteristic (ROC) analysis and the area under the ROC curve (ROC AUC). Model refits on the DAISY GP and FDR group were performed using the abovementioned multivariable logistic regression model. Improvement in prediction by additional markers was quantified using the integrated discrimination improvement, IDI. 22 Kaplan-Meier survival curves were obtained based on the resulting risk score and time from birth to development of T1D. Individuals lost to follow-up were treated as censored data. Differences in survival curves were assessed using log-rank tests. All analyses were performed using R version 3.2.0. 23 
| RESULTS
Using the 10-factor genetic risk model, risk scores were calculated for the 1941 individuals from the DAISY cohort with SNP data available. The genetic risk score distributions from DAISY participants, both GP and FDR, who were T1D cases vs those who did not develop T1D are shown in Figure 1 . For both GP and FDR, the children who developed T1D had a risk score distribution that was shifted to higher risk scores compared with those who did not progress to T1D.
The FDR participants showed a much broader distribution of risk scores than the GP individuals, whose risk scores were more tightly clustered. Interestingly, amongst the FDR children, both T1D cases and controls showed lower risk score distributions relative to the GP group, which can be explained by the HLA selection of the GP group.
In order to examine the discriminative power of the 10-factor model in DAISY GP and FDR subjects, these 2 subgroups were examined separately using the ROC AUC. Given the importance of HLA genotype, the ROC AUC was first calculated using HLA genotype as a sole predictor. A minimal risk model of 3 factors (HLA plus the top 2 weighted SNPs, PTPN22 and INS) and the full 10-factor model were also examined for discrimination between T1D and non-T1D outcomes ( Figure 2 ).
For both the GP and FDR groups, the probability of T1D outcome was calculated using HLA alone, the 3-factor model or the 10-factor model. In all cases, the mean risk score was higher in those who did indeed develop T1D than in those who did not. Thus, the discrimination slope, an estimation of the difference in probabilities of outcome, was positive for all 3 risk score calculations in both GP and FDR (Figure 3 ), The improvement in prediction by new or additional information can be quantified using the integrated discrimination improvement, IDI, an estimation in the difference in discrimination slopes. 22 Examination of the performance of the 10-factor model and the simpler 3-factor model relative to HLA risk group prediction, as well as to each other, was calculated in the DAISY GP and FDR groups. For the DAISY GP participants, both the 10-factor (P = .03) and the 3-factor (P = .03) models showed improvement over HLA alone ( Figure 3A ). Of note, in the GP group, comparison of the 10-factor model to the 3-factor model showed no significant improvement (P = .22), indicating that the adding 7 more
SNPs provided no additional information compared with the more minimal 3-factor model. In the DAISY FDR group, the 10-factor model showed improvement over both HLA alone (P = .01) and the 3-factor model (P = .02). However, there was no significant difference between the 3-factor model and HLA alone (P = .12, Figure 3B ). In order to demonstrate the impact of the various models on prediction, the 3 models were used to classify the GP (Table 1) and FDR (Table 2 ) study participants using a fixed sensitivity cutoff of . Comparison of classification performance using human leukocyte antigen (HLA) prediction alone vs 3-factor or 10-factor models in Diabetes Autoimmunity Study in the Young (DAISY) subjects recruited from (A) general population (GP) or (B) first-degree relatives (FDR) of type 1 diabetes (T1D) patients. Discrimination slope measures (difference in mean probability of T1D outcome) are given for risk score calculated by HLA, 3-factor or 10-factor model. Reclassification index integrated discrimination improvement (IDI) measures the improvement in classification performance for 1 model relative to another. *P < .05
The performance of the 10-factor risk model for predicting time to development of T1D was examined in the DAISY GP and FDR subgroups ( Figure 4 ). Children from each group were stratified by risk score into the upper quintile, middle 3 quintiles, and lower quintile.
Kaplan-Meier analysis was used to determine cumulative risk of development of T1D over follow-up from birth. The risk model showed significant discrimination for risk of development of T1D between the highest and lowest quintiles by risk score for both the GP ( Figure 4A , P = .00006) and FDR ( Figure 4B , P = .00022) groups.
Of note, amongst the GP group, those with risk scores in the bottom quintile showed no incidence of T1D over the first 15 years ( Figure 4B ) while in the highest quintile, T1D-free survival probability at 15 years was .88 (95% CI: .93, .81). For the DAISY FDR group, disease-free survival at 15 years in the highest vs lowest quintiles by risk score was .87 (95% CI: .92, .80) vs .98 (95% CI: .99, .92).
| DISCUSSION
While we 10, 19, 24, 25 and others [26] [27] [28] While the 10-factor model was significantly better at prediction of outcome than either HLA alone or the minimal 3-factor model in the FDR group, it showed no improvement over the 3-factor in the GP group. These findings may imply that children from the GP without a close family history of T1D may have a different profile of predictive minor genetic susceptibility genes from those with a T1D
FDR. The 10-factor model was developed in the T1DGC dataset, a cohort composed of families with multiple members diagnosed with FIGURE 4 Disease-free survival without type 1 diabetes (T1D) for Diabetes Autoimmunity Study in the Young (DAISY) general population (GP) and first-degree relatives (FDR) children, separated by highest risk score quintile (red), middle 3 risk quintiles (gray) and lowest risk quintile (blue) as determined using the 10-factor risk model. Time measured from birth to event. (A) GP subjects in DAISY cohort (highest vs lowest quintile, P-value = .00006) (B) First-degree relatives in DAISY cohort (highest vs lowest quintile, P-value = .00022) and UBASH3A (rs11203203 AA) were identified as being significantly associated with development of IA, while GLIS3 and IL2RA showed borderline association. 19 In addition, INS and UBASH3A (rs11203203 AA) were significantly associated with progression from IA to T1D, while PTPN22 showed borderline association. 19 We have shown that the 10-factor model derived by Winkler et al 10 is also able to effectively discriminate between children who are likely to progress to T1D over the next 15 years and those who
are not by survival analysis of longitudinal data. Of children from the DAISY cohort recruited from the GP, none of the children with a low risk score progressed to T1D over the follow-up time, indicating that the stratification by risk score is useful in GP children as well as FDR children, as previously described. 10 It is interesting to note that the GP children in the lowest risk quintile were largely from the lowest risk HLA group (DRx/DRx, where x represents the non-DR3 and non-DR4-DQ8 alleles) ( Figure S3 ), underlining the importance of HLA genotype for prediction of T1D risk.
One limitation of this study is the difference between the IL2RA SNP used for the DAISY cohort from the SNP identified in the risk modeling from the T1DGC cohort. While these SNPs are associated by linkage disequilibrium, the difference may be enough to affect the performance of the risk model. While the performance of the risk model in GP vs FDR groups is intriguing, the enrichment of the GP group for moderate and high-risk HLA types may limit the generalizability to the population as a whole. Another limitation of this study is the characteristics of the non-T1D group as it represents a group already selected for T1D risk. Overall, the ROC AUCs in the DAISY cohort were lower than the values in the T1DGC dataset and the German validation set described previously (.87 and .84, respectively), 10 although ROC AUC would be expected to be lower in a validation set. Also, both of the previously studied datasets contain a large group of control subjects who were from the GP and had only background risk for T1D. In contrast, the DAISY "control" groups consist of study subjects who were recruited because of their high-risk status as either a FDR or as having a high-risk HLA type and may still eventually progress to T1D in later life.
Although the majority of new onset patients with T1D have no family history, 1 the prevalence of T1D is relatively low in the GP, about .5% by age 20, use of these prediction models for GP screening would inevitably result in many false positives. 
